Work

A Tale of Two: 2-Year Outcomes of 2 Patients Undergoing Compassionate Use INTREPID and TricValve System Placement: Case Series

Year: 2025

Type: article

Abstract: Tricuspid regurgitation contributes to worsening heart failure symptoms, quality of life, and mortality. Medical therapy provides limited benefit, and surgical intervention in high-risk patients is associated with significant postoperative complications. Transcatheter tricuspid valve interventions are improving, but until recently, patient candidacy has been limited by the stringent inclusion and exclusion criteria of clinical trials. We present 2 cases of patients with severe tricuspid regurgitation treated in a compassionate use setting with transcatheter therapies. Patient 1 underwent TricValve (Products & Features) placement for mitigation of right-sided heart failure with at least 24 months free of hospitalization. Patient 2 underwent compassionate INTREPID valve (Medtronic) placement with at least 24 months free of heart failure-related hospitalization.

Source: Journal of the Society for Cardiovascular Angiography & Interventions

DOI: 10.1016/j.jscai.2025.103705

Authors: Hernan L. Vera-Sarmiento, Tsuyoshi Kaneko, Alan Zajarias

Institution: Washington University in St. Louis

Language: English

Topic: Cardiac Valve Diseases and Treatments

Subfield: Cardiology and Cardiovascular Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,400